First you march, then you run. From the #1 bestselling, award–winning team behind March comes the first book in their new, groundbreaking graphic novel series, Run: Book One “Run recounts the lost history of what too often follows dramatic change—the pushback of those who refuse it and the resistance of those who believe change has not gone far enough. John Lewis’s story has always been a complicated narrative of bravery, loss, and redemption, and Run gives vivid, energetic voice to a chapter of transformation in his young, already extraordinary life.” –Stacey Abrams “In sharing my story, it is my hope that a new generation will be inspired by Run to actively participate in the democratic process and help build a more perfect Union here in America.” –Congressman John Lewis To John Lewis, the civil rights movement came to an end with the signing of the Voting Rights Act in 1965. But that was after more than five years as one of the preeminent figures of the movement, leading sit–in protests and fighting segregation on interstate busways as an original Freedom Rider. It was after becoming chairman of SNCC (the Student Nonviolent Coordinating Committee) and being the youngest speaker at the March on Washington. It was after helping organize the Mississippi Freedom Summer and the ensuing delegate challenge at the 1964 Democratic National Convention. And after coleading the march from Selma to Montgomery on what became known as “Bloody Sunday.” All too often, the depiction of history ends with a great victory. But John Lewis knew that victories are just the beginning. In Run: Book One, John Lewis and longtime collaborator Andrew Aydin reteam with Nate Powell—the award–winning illustrator of the March trilogy—and are joined by L. Fury—making an astonishing graphic novel debut—to tell this often overlooked chapter of civil rights history.

Despite major advances in the understanding of stroke mechanisms that have occurred over the past quarter century, stroke continues to rank among the leading causes of death and disability worldwide. Although currently it may be difficult to believe, early doubts were expressed as to whether inter ventions in risk factors for either coronary disease or stroke would actually lead to a reduction in the incidence of these disorders. However, large clini cal trials in hypertension, carotid disease, atrial fibrillation, and antithrombotic and antiplatelet therapies have effectively demonstrated the efficacy of these targeted interventions in reducing stroke incidence. More recently, after earlier uncertainty regarding the role of elevated lipids as a risk factor for stroke, clinical trials of the statins have also demonstrated a significant reduction in the incidence of ischemic stroke. However, as em phasized in Handbook of Stroke Prevention in Clinical Practice, despite these gains and the initial decline in stroke incidence that did occur in the 1960s and 1970s, the incidence of stroke disappointingly has failed to show a fur ther significant decline since that time. The editors of Handbook of Stroke Prevention in Clinical Practice raise the very important question of whether recognized strategies for stroke preven tion have been widely or effectively implemented. They correctly empha size the critical importance of identifying the mechanism of stroke in each patient so as to properly direct prevention and treatment. As Dr.

Despite major advances in the understanding of stroke mechanisms that have occurred over the past quarter century, stroke continues to rank among the leading causes of death and disability worldwide. Although currently it may be difficult to believe, early doubts were expressed as to whether inter ventions in risk factors for either coronary disease or stroke would actually lead to a reduction in the incidence of these disorders. However, large clini cal trials in hypertension, carotid disease, atrial fibrillation, and antithrombotic and antiplatelet therapies have effectively demonstrated the efficacy of these targeted interventions in reducing stroke incidence. More recently, after earlier uncertainty regarding the role of elevated lipids as a risk factor for stroke, clinical trials of the statins have also demonstrated a significant reduction in the incidence of ischemic stroke. However, as em phasized in Handbook of Stroke Prevention in Clinical Practice, despite these gains and the initial decline in stroke incidence that did occur in the 1960s and 1970s, the incidence of stroke disappointingly has failed to show a fur ther significant decline since that time. The editors of Handbook of Stroke Prevention in Clinical Practice raise the very important question of whether recognized strategies for stroke preven tion have been widely or effectively implemented. They correctly empha size the critical importance of identifying the mechanism of stroke in each patient so as to properly direct prevention and treatment. As Dr."